[Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate].
Heidenreich
A
A
Klinik und Poliklinik für Urologie, Universität zu Köln.
D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary*; D004002:Clodronic Acid / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010146:Pain / Q000188:drug therapy*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D018712:Analgesics, Non-Narcotic; D000903:Antibiotics, Antineoplastic; D004002:Clodronic Acid; D015251:Epirubicin
Behandlung des hormonrefraktären Prostatakarzinoms mit schmerzhaften Knochenmetastasen. Epirubicin vs. Clodronat vs. Epirubicin plus Clodronat.